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Thromboembolic diseases of venous and arterial systems have historically been 
viewed as two different diseases with distinct risk factors.1 This notion was 
challenged in the last decade since an increased incidence of atherosclerosis and 
arterial thromboembolism (ATE) had been observed in subjects with venous 
thromboembolism (VTE).2-12 Moreover, an increasing amount of data indicated 
that classic atherosclerosis risk factors (ie, hypertension, hyperlipidemia, diabetes, 
obesity, and smoking) may also predispose individuals to VTE, though results were 
sometimes inconsistent.13-26  Moreover, not all data in literature support the 
hypothesis that VTE and ATE may be two different phenotypes of the same 
disease. For instance, hereditary thrombophilic deficiencies of the natural 
anticoagulant proteins (i.e., antithrombin, protein C and protein S) are considered 
strong risk factors for VTE; 27-29 while their association with ATE has been 
controversial.30,31  Similarly, overt proteinuria in patients with nephrotic syndrome 
is considered an established risk factor for VTE, while its association with ATE in 
non-diabetics has been less well recognized.32-34 Microalbuminuria on the other 
hand has been considered an established risk factor for ATE,35-39 whereas its 
association with VTE was for the first time studied in the current thesis. Finally, 
decreased estimated glomerular filtration rate (eGFR)  is also a long and well 
recognized risk factor for ATE,35,40 whereas its possible link to increased risk of 
VTE has been studied only recently.41 Thus whether VTE and ATE are two 
different entities or two different phenotypes of the same disease is a matter of 
intensive research in the field of cardiovascular research and has been the main 
topic of current thesis. 
 
Classic atherosclerosis risk factors and risk of venous thromboembolism  
The association of classic atherosclerosis risk factors (i.e., hypertension, 
dyslipidemia, smoking, obesity and diabetes) and incident VTE has been reported 
in various epidemiological studies.13-26 Although the exact pathophysiological 
mechanisms accounting for this potential association have yet to be unraveled, 
endothelial dysfunction, which is strongly associated with atherosclerosis risk 
factors, is considered the main culprit. This also fits the Virchow triad, as 
endothelial dysfunction or damage is one of the three components of the Virchow 
triad that historically classified the pathophysiological mechanisms of factors that 
may lead to VTE. In chapter 3 we assessed the association of various 
atherosclerosis risk factors and VTE. Whereas in univariate analysis various 
atherosclerosis risk factors were related to VTE, after age and sex adjustment only 
body mass index and albuminuria remained significant predictors of VTE. This 




demonstrates that crude association of atherosclerosis risk factors and VTE that is 
observed may be due to aging alone, and that in epidemiological studies 
appropriate adjustment or matching should take place. The results of studies 
investigating the association of atherosclerosis risk factors and incident VTE are 
consistently positive for overweight or obesity, whereas for hypertension, 
dyslipidemia, and diabetes these are equivocal.13-15,17-21,23-26 The differences 
between studies with respect to the predictive yield of these latter risk factors could 
be ascribed to differences in study populations with respect to presence of 
concomitant established and/or unknown VTE risk factors. For instance, subjects 
with diabetes may have a higher risk of VTE, but concomitant use of statins and/or 
antiplatelet agents in subjects with diabetes may neutralize this increased risk for 
VTE. Many of the studies that have been conducted thus far did not adjust for such 
potential confounders. In conclusion, at the moment there is insufficient data to 
consider hypertension, dyslipidemia, diabetes and smoking as established VTE risk 
factors. To assess whether there is an association of these variables with VTE, and 
whether these associations are causal, ideally clinical intervention studies should be 
conducted randomizing subjects to treatment or to no/less intensive treatment of 
these risk factors, with incident VTE serving as end-point. Of note, this may be less 
appropriate for dyslipidemia, because of the pleiotropic effects of statins.42 For 
dyslipidemia and smoking, prospective observational cohort studies that adjust for 
potential confounders might be a better choice to study their relevance as VTE risk 
factors.  
 
Thrombophilia and risk of venous and arterial thromboembolism 
Thrombophilia is the clinical term for a hypercoagulable state that was originally 
used to define young patients with VTE mainly due to hereditary defects. The five 
best established hereditary thrombophilic defects include the two prevalent gain-of-
function mutations (i.e., the factor V Leiden and the prothrombin G20210A 
mutation) and the relatively rare hereditary deficiencies of the natural anticoagulant 
proteins (i.e., protein S, protein C and antithrombin). Since these thrombophilic 
defects alone, or in combination with acquired risk factors, are responsible for only 
about 50-75% of VTE cases,43 it is likely that other unknown acquired and genetic 
risk factors eventually will be identified. Considering the fact that literature 
indicates that the later the identification of a thrombophilic defect, the weaker the 
associated risk of VTE, potential new hereditary risk factors are expected to be 
even weaker risk factors for VTE than the presently known factors. An exception 
to this assumption would be if thrombophilic families that have tested negative for 
Discussion and future perspectives 
 166 
the known hereditary defects are analyzed. However, any discovered new 
thrombophilic defects in such families will probably be family specific, be very 
rare and responsible for only a very low number of VTE on a population level. In 
contrast, if a risk factor is only weakly associated with VTE incidence, but highly 
prevalent in the general population, this may account for a considerable proportion 
of the overall VTE incidence at population level. At the same time the value of 
such a weak but prevalent risk factor for risk assessment at an individual patient 
level will be limited. Therefore, experts presently question the clinical relevance of 
screening for VTE prevention even for strong thrombophilic defects, such as the 
antithrombin, protein C and protein S deficiencies.44 Their uncertainty is primarily 
based on two reasons: first, in the setting of continuous thromboprophylaxis, the 
risk of major bleeding outweighs the risk of VTE in the general population;45 
second, in the setting of temporary external risk factors for VTE, 
thromboprophylaxis is momentarily recommended even in non-deficient subjects.46  
Hence, screening asymptomatic relatives of patients with protein S, protein C or 
antithrombin deficiencies may be unnecessary. Of note, the risk of bleeding 
associated with long-term oral anticoagulants in subjects with protein S, protein C 
or antithrombin deficiency might be lower than is reported in the general 
population.47 In chapter 6 we therefore assessed the absolute risks of VTE and the 
effect of screening on the VTE risk, in asymptomatic relatives of patients with 
protein S, protein C or antithrombin deficiency, in a prospective analysis. The 
overall VTE risks were comparable to the risks of VTE in our previous 
retrospective analysis,48 which was performed in these same thrombophilic 
families. Hence, screening and subsequent prophylactic recommendations may not 
affect the overall risk of VTE in relatives of protein S, protein C or antithrombin 
deficient patients. However, thromboprophylaxis was utilized in only half of all 
high-risk situations and still a trend for risk reduction of provoked VTE was 
observed. Moreover, all provoked VTE occurred when thromboprophylaxis was 
not used, underlining the effectiveness of thromboprophylaxis in these deficient 
subjects. On the other hand current guidelines strongly recommend 
thromboprophylaxis at time of high-risk situations such as surgery, 
immobilizations and trauma, even in non-deficient subjects.46 Consequently, 
augmentation of thromboprophylaxis in these settings, in accourdance with the 
prevailing guidelines, may make screening unnecessary as provoked VTE in 
deficient subjects would then also be reduced. Exceptions to this rule may be 
asymptomatic female relatives of patients with these deficiencies, as they are also 
exposed to higher VTE risk during pregnancy and oral contraceptive use. The 




possible relevance of discouraging oral contraceptive was demonstrated by the 
observation that 2 out of 6 deficient women using oral contraceptives developed 
VTE during oral contraceptives use (chapter 6). Therefore, screening of 
asymptomatic female relatives of patients with protein S, protein C or antithrombin 
deficiencies may be considered beneficial, because, if proven positive for the index 
deficiency, use of oral contraceptives should be discouraged in these women.  
 
Though the association of the known hereditary thrombophilic defects with VTE is 
well acknowledged, the risk of arterial thromboembolism (ATE) has been shown to 
be only slightly increased in subjects with Factor V Leiden or prothrombin 
G20210A mutation.49 Data on the association of protein S, protein C or 
antithrombin deficiencies with ATE is based on case-series and case-control 
studies that reported inconsistent results.30,31 As assessed in chapter 7, only protein 
S and protein C deficiencies, but not antithrombin deficiency, were risk factors for 
ATE before 55 years of age. That protein S and C deficiencies were found to be 
risk factors at young age could be ascribed to the fact that at higher age other ATE 
risk factors (i.e. classic atherosclerosis risk factors) overrule the risk of ATE 
conferred by these relatively weak risk factors (i.e., protein S and protein C 
deficiencies). Why only protein S and protein C deficiencies, but not antithrombin 
deficiency, were found to be associated with an increased risk of ATE might be 
due to non-anticoagulant effects of protein C and protein S.50-52 It could be 
speculated that the higher risk for ATE in subjects with protein C deficiency could 
be ascribed to the potent cytoprotective effects of the protein C pathway.51 The 
higher risk for ATE in subjects with protein S deficiency may be explained by the 
fact that protein S is synthesized by endothelial cells,52 whereas antithrombin is 
synthesized by hepatocytes. Endothelial injury as a trigger of thrombosis may 
therefore be enhanced by a preexisting defect in protein S synthesis at the site of 
injury. Furthermore, some cytoprotective effects also have been attributed to 
protein S.50,52  
 
In conclusion, even in thrombophilic families the risk of ATE is particularly driven 
by (classic) atherosclerosis risk factors. However, in young subjects without classic 
atherosclerosis risk factors, protein S or protein C deficiency increase the risk of 
ATE. In future studies, it will be interesting to assess any synergetic effects 
between thrombophilic defects and atherosclerosis risk factors for both venous and 
arterial thromboembolic events. Such studies, however, will be difficult to perform 
given the low prevalence of protein S, protein C and antithrombin deficiencies in 
Discussion and future perspectives 
 168 
the general population as (very) large numbers of participants will be necessary for 
this question. For the more prevalent factor V Leiden and the prothrombin 
G20210A mutation, however, such studies could be very well feasible.  
 
Risk of arterial thromboembolism in patients with prior venous 
thromboembolism 
Several studies have consistently shown that the risk of ATE in subjects with prior 
VTE is higher than in matched controls.2,3,5,10,11 In contrast, studies in subjects with 
VTE reported contradictory results with respect to the presence of asymptomatic 
atherosclerotic lesions.4,6,8,9,12 If atherosclerosis is not or less associated with VTE, 
it may be postulated that the higher risk of ATE after VTE is probably due to 
medical conditions that predispose to both VTE and ATE. Examples of such 
predisposing conditions are cancer, antiphospholipid antibodies, infectious 
diseases, use of hormonal therapy and renal disease.  On the other hand, thrombus 
formation in each the arterial and venous system is due to platelet aggregation and 
coagulation activation, which may also explain the stronger and more consistent 
association of VTE with subsequent ATE, as compared to the association of VTE 
with asymptomatic atherosclerosis. Moreover, the high risk of ATE especially after 
idiopathic VTE indicates that the association of VTE with subsequent ATE is not 
only due to aforementioned predisposing conditions. Another remarkable fact is 
that the risk of ATE after VTE is particularly high in the first year after diagnosis 
of VTE,11 as we also observed in chapter 8. This is surprising because the standard 
treatment for VTE, which consists of 3 to 6 months of oral anticoagulant drugs, 
should have lowered the risk of ATE. A possible explanation includes inaccuracy 
in the exact dates of the two diagnoses, because data were based on hospital 
registries that may be prone to inaccurate date entry. Other possibilities include: 1) 
Failure to restart aspirin after cessation of anticoagulant therapy in patients who 
were on aspirin before VTE diagnosis. 2) In addition to the anticoagulant effects of 
vitamin K antagonists by blocking γ – carboxylation of various vitamin K 
dependent coagulation factors in the liver, these drugs may also promote arterial 
calcification by blocking γ – carboxylation of peripheral vitamin K dependent 
proteins.53-55 In a recent small cross-sectional study long-term (>10 years) use of 
vitamin K antagonists was indeed associated with increased extracoronary arterial 
calcification.53 Two potentially important peripheral vitamin K dependent proteins 
are Matrix Gla protein (MGP) and Growth Arrest Specific gene 6 protein (Gas-6).54 
These proteins have many diverse biologic functions. Produced by vascular smooth 
muscle cells, MGP functions primarily as a vascular calcification inhibitor and 




Gas-6 affects vascular smooth muscle cell movement and apoptosis.54 On the other 
hand, it should be mentioned that the vitamin K antagonists appeared effective in 
various trials in ATE prevention that could be ascribed to the anticoagulant effects 
of these drugs.56,57 3) Finally, patients with VTE might be diagnosed earlier with 
subsequent ATE in the first year due to enrollment in the medical circuit. 
 
For clinical implications, an important issue that warrants attention is the 
effectiveness of statins in the prevention of VTE. It is assumed that the VTE risk 
reduction by these drugs is not due to their cholesterol-lowering effects, but rather 
to the pleiotropic effects of statins.42 These include particularly endothelial 
stabilization that is accompanied by reduction of among others the tissue factor 
levels and reduction of thrombin generation.42 The JUPITER trial indeed reported 
primary VTE risk reduction in the intervention arm with rosuvastatin as compared 
to the placebo-controlled arm.58 Use of statin therapy in secondary preventions of 
VTE probably may have more clinical implications. Since patients with VTE have 
a high risk of recurrent VTE (about 5% in the first year)59 and – as we know now – 
also an increased risk of ATE, prospective randomized trials are needed to address 
the effect of statin therapy on VTE recurrence and ATE incidence after a prior 
VTE. The Du Lac randomized trial will address this issue. In this trial, subjects 
with a VTE, after cessation of standard oral anticoagulants treatment of 6 months, 
will be randomized to a maintenance intervention-arm with rosuvastatin versus a 
control-arm with placebo. All patients will be followed for 2 years with recurrent 
VTE serving as the primary endpoint, and the development of ATE as one of the 
secondary endpoints. 
 
Renal disease and risk of venous and arterial thromboembolism 
As presented in chapter 1, renal disease with overt proteinuria predisposes to both 
VTE and ATE. Though this association was assumed for decades, the absolute 
risks were unknown, due to lack of data on large patient cohorts. In chapter 2 we 
assessed the absolute risk of VTE (1.02% per year) and ATE (1.48% per year), in a 
large cohort of patients with nephrotic-range proteinuria. These risks were each 
about 8-fold higher than the age- and sex-weighted absolute risks in the general 
population. Compared with the general population, the risk of both VTE (about 140 
fold) and ATE (about 50 fold) were particularly high in the first 6 months after 
diagnosis of nephrotic-range proteinuria. Therefore, one might consider primary 
thrombo-prophylaxis during this period. However, given the bleeding risk 
associated with the use of anticoagulants,45 in the setting of proteinuria-related 
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hypercoagulability, safer therapies such as antiproteinuric medications and statins 
warrants evaluation first. Indeed, our unpublished retrospective observational data 
in this same cohort of patients indicated that statin therapy was associated with a 
50% reduction of the VTE risk (data not shown). Furthermore, in chapter 5 we 
assessed the effect of antiproteinuric therapy (i.e. losartan alone or in combination 
with diuretics and/or low sodium diet) on the procoagulant state in proteinuric 
patients. Antiproteinuric therapy indeed reversed the prothrombotic state in these 
patients, re-emphasizing the importance of proteinuria reduction as a treatment 
target. The pathophysiological mechanisms responsible for the increased risk of 
thromboembolism in patients with nephrotic-range proteinuria are unclear. 
Alterations in plasma levels of proteins involved in coagulation and fibrinolysis, 
urinary antithrombin loss, enhanced platelet aggregation, hyperviscosity, and 
hyperlipidemia are all considered to be predisposing factors.34,60-62 Of these, 
changes in the levels of plasma coagulation proteins and loss of antithrombin in the 
urine have been historically considered the main predisposing factors, especially 
for VTE. In contrast with these historical assumptions, we observed in chapter 5 
that the levels of plasma antithrombin levels in patients with proteinuria were 
similar as in healthy controls, whereas all procoagulant proteins were elevated in 
these patients. Interestingly, except antithrombin, all pro- and other anticoagulant 
proteins were positively associated with the extent of proteinuria and inversely 
associated with serum albumin. The higher levels of various coagulation proteins in 
patients with proteinuria are assumed to be secondary to the decrease in levels of 
serum albumin, as in response to this decrease in serum albumin the liver 
upregulates the production of all liver-synthesized proteins, including coagulation 
proteins and lipoproteins.63 We postulate that upregulation of antithrombin 
synthesis might be counterbalanced by urinary loss. Antithrombin has a relatively 
low molecular weight, comparable to the molecular weight of albumin, and will 
therefore easily leak via the glomeruli in (pre)urine. Indeed, in a small pilot study, 
including three patients with proteinuria ranging from 0.5 g/d to 1.5 g/d, we could 
confirm urinary loss of considerable amounts of antithrombin (6-21%).  
 
At the population level,  the association of  microalbuminuria or a mildly decreased 
eGFR (i.e. stage 1-3 chronic kidney disease, CKD) with thromboembolism is more 
relevant than that of nephrotic-range proteinuria, due to the higher prevalence of 
stage 1-3 CKD when compared to the prevalence of overt proteinuria (10-12% 
versus <0.1% of the general population, respectively).64,65 Whereas the association 
of microalbuminuria and decreased eGFR with ATE is well-recognized,35-40 we 




described for the first time the association of microalbuminuria (i.e. mainly stage 1-
2 CKD) with VTE in the Prevention of REnal and Vascular ENd-stage Disease 
(PREVEND) study (chapter 3). The association of decreased eGFR (i.e. CKD 
stage 3-4) with VTE was for the first time described by the investigators of the 
Longitudinal Investigation of Thromboembolism Etiology (LITE) project, which 
comprises the pooled data of the Atherosclerosis Risk in Communities (ARIC) 
study and the Cardiovascular Health Study (CHS).41,66 As described in chapter 4 
the association of decreased eGFR and VTE in the PREVEND study was 
particularly driven by the presence of albuminuria of ≥30 mg/24h, while the ARIC 
study suggested that microalbuminuria had no significant association with VTE 
risk,66 and that only eGFR showed an inverse association with VTE incidence. 
These discrepancies between the ARIC and the PREVEND studies could possibly 
be ascribed to differences in characteristics of the enrolled study participants. In the 
PREVEND study increased hazard ratios of VTE by eGFR level have been 
described that were comparable to those found in ARIC, but these did not reach 
statistical significance, which is likely due to limited power. In the PREVEND 
study a relatively limited number of subjects with more severely decreased eGFR 
participated. The PREVEND study is better powered to investigate the predictive 
value of albuminuria due to the enrichment of this study cohort with albuminuric 
subjects. The ARIC study on the other hand, is probably better powered for 
subjects with lower eGFR given the larger sample size and higher number of VTE 
events, but under-powered for albuminuria.66 The weaker hazard ratio conferred by 
albuminuria in ARIC as compared to PREVEND, may be due to several reasons. In 
PREVEND albuminuria is assessed in 24hr urine samples, the gold standard, that 
were not frozen before assessment. Frozen storage is known to induce a systematic 
decrease and more variability in albuminuria concentration.67 Furthermore, subjects 
with microalbuminuria in ARIC are mainly diabetics, while in PREVEND these 
are mainly non-diabetics, as per protocol insulin-using diabetics were excluded in 
PREVEND. This may have influenced the risk estimates, as diabetic subjects are 
usually on statin therapy and these subjects are more frequently treated for their 
cardiovascular morbidity with anti-platelet medication. To assess more definitively 
whether either eGFR or microalbuminuria or both are independent risk factors for 
VTE we are currently preparing a pooled individual patient level analysis of 
several databases, among others PREVEND and ARIC to increase the statistical 
power to address this issue. 
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The exact pathophysiological mechanisms linking decreased eGFR and increased 
albuminuria to VTE have yet to be identified. However, endothelial dysfunction 
might be the main culprit of this link that, in turn, is associated with mild 
coagulation disturbances, such as increased levels of factor VIII and plasminogen 
activator inhibitor-1.68-70 This is in contrast to the situation with nephrotic-range 
proteinuria, in which coagulation disturbances probably play a more prominent 
role. However, these assumptions are merely based on literature, as we did not 
assess endothelial dysfunction in either microalbuminuric subjects or in patients 
with nephrotic-range proteinuria. In the near future we are planning to assess the 
exact coagulation disturbances in patients with microalbuminuria. Depending on 
the results, it will subsequently be interesting to assess the impact of antiproteinuric 
therapy with for example losartan and the effect of statins on the coagulation 
disturbances in subjects with microalbuminuria.  
 
As compared to the risk of VTE, the risk of ATE in patients with CKD is relatively 
better established. In a recent meta-analysis by the CKD Prognosis Consortium the 
independent association of both eGFR and albuminuria with ATE was confirmed, 
using pooled data of 21 general population-based cohorts with over one million 
study participants.40 Separate meta-analyses of the same consortium addressing the 
same issues in other populations, such as those at high risk of CKD and those with 
known CKD, are currently submitted. Notably, the classification of CKD according 
to the 2002 KDOQI classification has been increasingly criticized in the field of 
nephrology.71 These criticisms ranged from terminology, methodology, definition, 
classification to prognosis. Based on the four meta-analyses by the CKD Prognosis 
Consortium a proposal for a new guideline to reclassify CKD is being developed. 
Of note, this consortium is led by the department of Nephrology of the University 
Medical Center Groningen and the department of Epidemiology and Clinical 
Research of the Johns Hopkins University in Baltimore, USA.  
 






In conclusion, VTE and ATE share some, such as obesity and renal disease, but not 
all risk factors as summarized in the above Figure. Even for those risk factors that 
seem to be associated with both VTE and ATE the associations with each of both 
endpoints are in general not of similar strength. There may be at least one 
exception. Urinary protein loss, ranging from microalbuminuria to nephrotic-range 
proteinuria, turned out to be associated with similar relative risks for VTE and 
ATE. Based on the current available data, it seems therefore that VTE and ATE are 
probably not different phenotypes of the same disease, but rather different 
multifactorial diseases that share some risks factors. Nevertheless, a shared 
preventative intervention might be beneficial that needs to be addressed in future 
studies. Especially, the role of albuminuria lowering by intervention in the renin-
angiotensin-aldosterone system and the use of statins are interesting and could be 
highly relevant for prevention of recurrent VTE and prevention of ATE in patients 
with a prior VTE.  
Figure. Association of risk factors with arterial and venous thromboembolism. 
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